Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis following COVID-19 BBIBP-CorV vaccine: A case report

Parisa Javadian, Negin Fadaei-Tirani, Zainab Amoosoltani-Forooshani,Vahid Reisi-Vanani,Mina Borran

Clinical Infection in Practice（2024）

引用 0|浏览0

暂无评分

摘要

•ANCA-associated vasculitis following COVID-19 vaccination is a rare but serious reaction.•ANCA-associated vasculitis could mimic the infectious disease clinical course, accordingly leading to misdiagnosis and outcome deterioration.•Tocilizumab could be a candidate for treating ANCA-associated vasculitis after further clinical study.•Researchers should consider autoimmune adverse effects in future vaccine design.

查看译文

关键词

COVID-19,Vaccine,ANCA-associated vasculitis,Case report

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要